If your B12 is already in a healthy range, extra B12 is unlikely to cause large weight-loss effects on its own
Both medications affect appetite and digestion, and both interact with the metabolic changes of menopause
Cost: Topical is a steady ongoing expense (cream or serum supply)
Customers tell us they want peace of mind so that if a consumer has their beverage across multiple day parts, they will have a large margin before hitting tolerance levels. Why beverage brands need to brace themselves The thirst for GLP-1 medication only looks set to increase among consumers with the launch of unfussy, non-injectable formats A pill version of the appetite-suppressing drug, Wegovy, was unveiled by pharma giant Novo Nordisk in January Eli Lilly & Co is preparing to debut its own oral version, Orforglipron, post-FDA approval later this year The total GLP-1 pill market is forecast to leap from $3.2bn in 2025 to 34.3 bn in 2031, a CAGR of 48.4% (GlobalData) (Source GlobalData) GLP-1 drink NPD outside the box Although, its not just traditional food and beverage companies developing tailored NPD
Paladugu L, Gharaibeh A, Kolli N, Learman C, Hall TC, Li L, et al
Whats next: Final phase 2 data will include results from the maintenance phase (weeks 2652)
